Pasar al contenido principal

ESTUDIO DE LAS FUNCIONES ESPECIFICAS DE PARP-1 Y DE PARP-2 EN TUMORES CON ALTERACIONES EN C-MYC

PID2020-112526RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO INSTITUT HOSPITAL DEL MAR D'INVESTIGACIONS MEDIQUES

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Attenuation of muscle damage, structural abnormalities, and physical activity in respiratory and limb muscles following treatment with rucaparib in lung cancer cachexia mice

  • Pérez-Peiró, Maria
  • Duran Jordà, Xavier, 1974-
  • Yélamos López, José
  • Barreiro Portela, Esther
Overactivation of poly (ADPribose) polymerases (PARPs) is involved in cancer-induced cachexia. We hypothesized that the PARP inhibitor rucaparib may improve muscle mass and reduce damage in cancer cachexia mice. In mouse diaphragm and gastrocnemius (LP07 lung adenocarcinoma) treated with PARP inhibitor (rucaparib,150 mg/kg body weight/24 h for 20 days) and in non-tumor control animals, body, muscle, and tumor weights; tumor area; limb muscle strength; physical activity; muscle structural abnormalities, damage, and phenotype; PARP activity; and proteolytic and autophagy markers were quantified. In cancer cachexia mice compared to non-cachexia controls, body weight and body weight gain, muscle weight, limb strength, physical activity, and muscle fiber size significantly declined, while levels of PARP activity, plasma troponin I, muscle damage, and proteolytic and autophagy markers increased. Treatment with the PARP inhibitor rucaparib elicited a significant improvement in body weight gain, tumor size and weight, physical activity, muscle damage, troponin I, and proteolytic and autophagy levels. PARP pharmacological inhibition did not exert any significant improvements in muscle weight, fiber size, or limb muscle strength. Treatment with rucaparib, however, improved muscle damage and structural abnormalities and physical activity in cancer cachexia mice. These findings suggest that rucaparib exerts its beneficial effects on cancer cachexia performance through the restoration of muscle structure., Project “FI19/00001” funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. María Pérez-Peiró was a recipient of a predoctoral fellowship from FIS Contratos Predoctorales de Formación en Investigación en Salud. The current research has been supported by project FIS 18/00075 funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union and CIBERES 2021 funded by Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Science and Innovation; Spanish Respiratory Society (SEPAR), SEPAR 2018. The Yélamos lab is funded by the Spanish Ministry of Science and Innovation (grant PID2020-112526RB-I00 funded by MCIN/AEI/10.13039/501100011033).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Attenuation of tumor burden in response to rucaparib in lung aAdenocarcinoma: the contribution of oxidative stress, apoptosis, and DNA damage

  • Pérez-Peiró, Maria
  • Valentí-Serra, Paula
  • León-González, Blanca
  • Ampurdanés, Coral
  • Duran, Xavier
  • Yélamos López, José
  • Barreiro Portela, Esther
In cancer, overactivation of poly (ADPribose) polymerases (PARP) plays a relevant role in DNA repair. We hypothesized that treatment with the PARP inhibitor rucaparib may reduce tumor burden via several biological mechanisms (apoptosis and oxidative stress) in mice. In lung tumors (LP07 lung adenocarcinoma) of mice treated/non-treated (control animals) with PARP inhibitor (rucaparib,150 mg/kg body weight/24 h for 20 day), PARP activity and expression, DNA damage, apoptotic nuclei, cell proliferation, and redox balance were measured using immunoblotting and immunohistochemistry. In lung tumors of rucaparib-treated mice compared to non-treated animals, tumor burden, PARP activity, and cell proliferation decreased, while DNA damage, TUNEL-positive nuclei, protein oxidation, and superoxide dismutase content (SOD)2 increased. In this experiment on lung adenocarcinoma, the pharmacological PARP inhibitor rucaparib elicited a significant improvement in tumor size, probably through a reduction in cell proliferation as a result of a rise in DNA damage and apoptosis. Oxidative stress and SOD2 also increased in response to treatment with rucaparib within the tumor cells of the treated mice. These results put the line forward to the contribution of PARP inhibitors to reduced tumor burden in lung adenocarcinoma. The potential implications of these findings should be tested in clinical settings of patients with lung tumors., This study has been funded by Instituto de Salud Carlos III through the project “FI19/00001” (Co-funded by European Social Fund “Investing in your future”). María Pérez-Peiró was a recipient of a predoctoral fellowship from FIS Contratos Predoctorales de Formación en Investigación en Salud. The current research has been supported by project FIS 18/00075 funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union and Consorcio Centro de Investigación Biomédica en Red (CIBERES) 2022 funded by Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Science and Innovation and European Union; Spanish Respiratory Society (SEPAR), contract grant numbers, SEPAR 2018. The Yélamos lab is funded by the Spanish Ministry of Science and Innovation (grant PID2020-112526RB-I00 funded by MCIN/AEI/10.13039/501100011033).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice

  • Galindo-Campos, M. A.
  • Lutfi, Nuria
  • Bonnin, S.
  • Martínez, C.
  • Velasco-Hernández, Talia
  • García-Hernández, V.
  • Martín Caballero, Juan
  • Ampurdanés, Coral
  • Gimeno, R.
  • Colomo, L.
  • Roué, Gaël
  • Guilbaud, G.
  • Dantzer, Françoise
  • Navarro Medrano, Pilar
  • Murga, Matilde
  • Fernández-Capetillo, Óscar
  • Bigas, A.
  • Menéndez, Pablo
  • Sale; J. E.
Dysregulation of the c-Myc oncogene occurs in a wide variety of hematologic malignancies, and its overexpression has been linked with aggressive tumor progression. Here, we show that poly (ADP-ribose) polymerase 1 (PARP-1) and PARP-2 exert opposing influences on progression of c-Myc-driven B-cell lymphoma. PARP-1 and PARP-2 catalyze the synthesis and transfer of ADP-ribose units onto amino acid residues of acceptor proteins in response to DNA strand breaks, playing a central role in the response to DNA damage. Accordingly, PARP inhibitors have emerged as promising new cancer therapeutics. However, the inhibitors currently available for clinical use are not able to discriminate between individual PARP proteins. We found that genetic deletion of PARP-2 prevents c-Myc-driven B-cell lymphoma, whereas PARP-1 deficiency accelerates lymphomagenesis in the E¿-Myc mouse model of aggressive B-cell lymphoma. Loss of PARP-2 aggravates replication stress in preleukemic E¿-Myc B cells, resulting in accumulation of DNA damage and concomitant cell death that restricts the c-Myc-driven expansion of B cells, thereby providing protection against B-cell lymphoma. In contrast, PARP-1 deficiency induces a proinflammatory response and an increase in regulatory T cells, likely contributing to immune escape of B-cell lymphoma, resulting in an acceleration of lymphomagenesis. These findings pinpoint specific functions for PARP-1 and PARP-2 in c-Myc-driven lymphomagenesis with antagonistic consequences that may help inform the design of new PARP-centered therapeutic strategies, with selective PARP-2 inhibition potentially representing a new therapeutic approach for the treatment of c-Myc-driven tumors., The J.Y. laboratory is funded by the Spanish Ministerio de Economía, Industria y Competitividad (grant SAF2017-83565-R), Spanish Ministerio de Ciencia e Innovación (grant PID2020-112526RB-I00), and Fundación Científica de la Asociación Española Contra el Cáncer (grant PROYEI6018YÉLA). Work in the J.E.S. laboratory is supported by a core grant to the Laboratory of Molecular Biology from the Medical Research Council (U105178808). The F.D. laboratory is supported by a Laboratory of Excellence grant (ANR-10-LABX-0034_Medalis) to Strasbourg University, Centre National de la Recherche Scientifique. The P.N. laboratory is supported by grants from the Spanish Ministry of Economy and Competitiveness/Instituto de Salud Carlos III–Fondo Europeo de Desarrollo Regional (FEDER; PI17/00199 and PI20/00625) and the Generalitat de Catalunya (2017-SGR-225). The P.M. laboratory acknowledges support from Centres de Recerca de Catalunya/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support, the Spanish Ministry of Economy and Competitiveness (grant SAF-2019-108160-R), the Fundación Uno entre Cienmil, the Obra Social La Caixa (grant LCF/PR/HR19/52160011), and the German Josep Carreras Leukamie Stiftung. Work at the G.R. and P.M. laboratories are cofinanced by the European Regional Development Fund through the Interreg V-A Spain-France-Andorra Program (project PROTEOblood; grant EFA360/19). The O.F.-C. laboratory is funded by grants from the Spanish Ministry of Science, Innovation and Universities (RTI2018-102204-B-I00; cofinanced with European FEDER funds) and the European Research Council (ERC-617840). T.V.-H. was supported by a Marie Sklodowska Curie fellowship (GA792923). The A.B. laboratory is supported by the Spanish Ministry of Economy and Competitiveness (grant PID2019-104695RB-I00)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Attenuation of muscle damage, structural abnormalities, and physical activity in respiratory and limb muscles following treatment with rucaparib in lung cancer cachexia mice

  • Pérez-Peiró, Maria
  • Duran Jordà, Xavier, 1974-
  • Yélamos López, José
  • Barreiro Portela, Esther
Overactivation of poly (ADPribose) polymerases (PARPs) is involved in cancer-induced cachexia. We hypothesized that the PARP inhibitor rucaparib may improve muscle mass and reduce damage in cancer cachexia mice. In mouse diaphragm and gastrocnemius (LP07 lung adenocarcinoma) treated with PARP inhibitor (rucaparib,150 mg/kg body weight/24 h for 20 days) and in non-tumor control animals, body, muscle, and tumor weights; tumor area; limb muscle strength; physical activity; muscle structural abnormalities, damage, and phenotype; PARP activity; and proteolytic and autophagy markers were quantified. In cancer cachexia mice compared to non-cachexia controls, body weight and body weight gain, muscle weight, limb strength, physical activity, and muscle fiber size significantly declined, while levels of PARP activity, plasma troponin I, muscle damage, and proteolytic and autophagy markers increased. Treatment with the PARP inhibitor rucaparib elicited a significant improvement in body weight gain, tumor size and weight, physical activity, muscle damage, troponin I, and proteolytic and autophagy levels. PARP pharmacological inhibition did not exert any significant improvements in muscle weight, fiber size, or limb muscle strength. Treatment with rucaparib, however, improved muscle damage and structural abnormalities and physical activity in cancer cachexia mice. These findings suggest that rucaparib exerts its beneficial effects on cancer cachexia performance through the restoration of muscle structure., Project “FI19/00001” funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. María Pérez-Peiró was a recipient of a predoctoral fellowship from FIS Contratos Predoctorales de Formación en Investigación en Salud. The current research has been supported by project FIS 18/00075 funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union and CIBERES 2021 funded by Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Science and Innovation; Spanish Respiratory Society (SEPAR), SEPAR 2018. The Yélamos lab is funded by the Spanish Ministry of Science and Innovation (grant PID2020-112526RB-I00 funded by MCIN/AEI/10.13039/501100011033).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Attenuation of tumor burden in response to rucaparib in lung aAdenocarcinoma: the contribution of oxidative stress, apoptosis, and DNA damage

  • Pérez-Peiró, Maria
  • Valentí-Serra, Paula
  • León-González, Blanca
  • Ampurdanés, Coral
  • Duran, Xavier
  • Yélamos López, José
  • Barreiro Portela, Esther
In cancer, overactivation of poly (ADPribose) polymerases (PARP) plays a relevant role in DNA repair. We hypothesized that treatment with the PARP inhibitor rucaparib may reduce tumor burden via several biological mechanisms (apoptosis and oxidative stress) in mice. In lung tumors (LP07 lung adenocarcinoma) of mice treated/non-treated (control animals) with PARP inhibitor (rucaparib,150 mg/kg body weight/24 h for 20 day), PARP activity and expression, DNA damage, apoptotic nuclei, cell proliferation, and redox balance were measured using immunoblotting and immunohistochemistry. In lung tumors of rucaparib-treated mice compared to non-treated animals, tumor burden, PARP activity, and cell proliferation decreased, while DNA damage, TUNEL-positive nuclei, protein oxidation, and superoxide dismutase content (SOD)2 increased. In this experiment on lung adenocarcinoma, the pharmacological PARP inhibitor rucaparib elicited a significant improvement in tumor size, probably through a reduction in cell proliferation as a result of a rise in DNA damage and apoptosis. Oxidative stress and SOD2 also increased in response to treatment with rucaparib within the tumor cells of the treated mice. These results put the line forward to the contribution of PARP inhibitors to reduced tumor burden in lung adenocarcinoma. The potential implications of these findings should be tested in clinical settings of patients with lung tumors., This study has been funded by Instituto de Salud Carlos III through the project “FI19/00001” (Co-funded by European Social Fund “Investing in your future”). María Pérez-Peiró was a recipient of a predoctoral fellowship from FIS Contratos Predoctorales de Formación en Investigación en Salud. The current research has been supported by project FIS 18/00075 funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union and Consorcio Centro de Investigación Biomédica en Red (CIBERES) 2022 funded by Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Science and Innovation and European Union; Spanish Respiratory Society (SEPAR), contract grant numbers, SEPAR 2018. The Yélamos lab is funded by the Spanish Ministry of Science and Innovation (grant PID2020-112526RB-I00 funded by MCIN/AEI/10.13039/501100011033).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice

  • Galindo Campos, Miguel A.|||0000-0002-0650-8660
  • Lutfi, Nura
  • Bonnin, Sarah|||0000-0001-5159-2518
  • Martínez Cáceres, Carlos|||0000-0003-3307-1326
  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • García-Hernández, Violeta|||0000-0003-2328-4360
  • Martín Caballero, Juan
  • Ampurdanés, Coral
  • Gimeno, Ramón|||0000-0002-8758-121X
  • Colomo, Luis|||0000-0001-5236-5085
  • Roué, Gaël|||0000-0003-0245-2257
  • Guilbaud, Guillaume|||0000-0002-4345-6855
  • Dantzer, Françoise
  • Navarro, Pilar|||0000-0003-4314-4584
  • Murga, Matilde|||0000-0002-9766-4481
  • Fernández Capetillo, Oscar|||0000-0002-2690-6885
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Sale, Julian E.
  • Yélamos, José|||0000-0003-1195-1496
Dysregulation of the c-Myc oncogene occurs in a wide variety of hematologic malignancies, and its overexpression has been linked with aggressive tumor progression. Here, we show that poly (ADP-ribose) polymerase 1 (PARP-1) and PARP-2 exert opposing influences on progression of c-Myc-driven B-cell lymphoma. PARP-1 and PARP-2 catalyze the synthesis and transfer of ADP-ribose units onto amino acid residues of acceptor proteins in response to DNA strand breaks, playing a central role in the response to DNA damage. Accordingly, PARP inhibitors have emerged as promising new cancer therapeutics. However, the inhibitors currently available for clinical use are not able to discriminate between individual PARP proteins. We found that genetic deletion of PARP-2 prevents c-Myc-driven B-cell lymphoma, whereas PARP-1 deficiency accelerates lymphomagenesis in the Eμ-Myc mouse model of aggressive B-cell lymphoma. Loss of PARP-2 aggravates replication stress in preleukemic Eμ-Myc B cells, resulting in accumulation of DNA damage and concomitant cell death that restricts the c-Myc-driven expansion of B cells, thereby providing protection against B-cell lymphoma. In contrast, PARP-1 deficiency induces a proinflammatory response and an increase in regulatory T cells, likely contributing to immune escape of B-cell lymphoma, resulting in an acceleration of lymphomagenesis. These findings pinpoint specific functions for PARP-1 and PARP-2 in c-Myc-driven lymphomagenesis with antagonistic consequences that may help inform the design of new PARP-centered therapeutic strategies, with selective PARP-2 inhibition potentially representing a new therapeutic approach for the treatment of c-Myc-driven tumors.